PSNL vs. ENZ, XGN, DMTK, BDSX, SERA, AFMD, JATT, TPST, LFVN, and FORA
Should you be buying Personalis stock or one of its competitors? The main competitors of Personalis include Enzo Biochem (ENZ), Exagen (XGN), DermTech (DMTK), Biodesix (BDSX), Sera Prognostics (SERA), Affimed (AFMD), JATT Acquisition (JATT), Tempest Therapeutics (TPST), LifeVantage (LFVN), and Forian (FORA). These companies are all part of the "medical" sector.
Personalis (NASDAQ:PSNL) and Enzo Biochem (NYSE:ENZ) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, community ranking, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.
Enzo Biochem received 102 more outperform votes than Personalis when rated by MarketBeat users. However, 65.48% of users gave Personalis an outperform vote while only 56.53% of users gave Enzo Biochem an outperform vote.
Enzo Biochem has lower revenue, but higher earnings than Personalis.
Personalis currently has a consensus price target of $5.00, suggesting a potential upside of 228.95%. Given Personalis' higher probable upside, equities analysts plainly believe Personalis is more favorable than Enzo Biochem.
In the previous week, Personalis had 18 more articles in the media than Enzo Biochem. MarketBeat recorded 19 mentions for Personalis and 1 mentions for Enzo Biochem. Enzo Biochem's average media sentiment score of 1.00 beat Personalis' score of 0.79 indicating that Enzo Biochem is being referred to more favorably in the news media.
Personalis has a beta of 1.91, suggesting that its share price is 91% more volatile than the S&P 500. Comparatively, Enzo Biochem has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500.
Enzo Biochem has a net margin of 99.28% compared to Personalis' net margin of -124.89%. Enzo Biochem's return on equity of -36.71% beat Personalis' return on equity.
61.9% of Personalis shares are owned by institutional investors. Comparatively, 36.9% of Enzo Biochem shares are owned by institutional investors. 4.1% of Personalis shares are owned by insiders. Comparatively, 15.5% of Enzo Biochem shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Enzo Biochem beats Personalis on 8 of the 15 factors compared between the two stocks.
Get Personalis News Delivered to You Automatically
Sign up to receive the latest news and ratings for PSNL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PSNL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Personalis Competitors List
Related Companies and Tools
